Journal of Hepatology
Volume 52, Issue 5 , Pages 652-657 , May 2010

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis

  • Ana-Carolina Cardoso

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • These authors contributed equally to this work.
    • ,
  • Rami Moucari

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • These authors contributed equally to this work.
    • ,
  • Claudio Figueiredo-Mendes

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Marie-Pierre Ripault

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Nathalie Giuily

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Corinne Castelnau

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Nathalie Boyer

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Tarik Asselah

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Michelle Martinot-Peignoux

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Sarah Maylin

      Affiliations

    • Service de Microbiologie, Hôpital Beaujon, AP-HP, Clichy, France
    • ,
  • Roberto J. Carvalho-Filho

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Dominique Valla

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • ,
  • Pierre Bedossa

      Affiliations

    • Service d’Anatomie Pathologique, Hôpital Beaujon, AP-HP, Clichy, France
    • ,
  • Patrick Marcellin

      Affiliations

    • Service d’Hépatologie, Hôpital Beaujon, AP-HP, INSERM U773-CRB3, Université Denis Diderot-Paris7, 100 Boulevard du Général Leclerc, 92110 Clichy, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 4087 5338; fax: +33 1 4730 9440.

Received 10 August 2009 ,Revised 27 November 2009 ,Accepted 1 December 2009.

References 

  1. World Health Organization. Mortality database. Available from: http://www.who.int/whosis/en/ [accessed 11.05.07].
  2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50
  3. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology. 2006;43:1303–1310
  4. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–472
  5. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745–750
  6. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  7. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonk M, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870–1875
  8. Camma C, Giunta M, Andreone P, Craxì A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence based approach. J Hepatol. 2001;34:593–602
  9. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579–587
  10. Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology. 2004;127:S294–S302
  11. Craxì A, Camma C. Prevention of hepatocellular carcinoma. Clin Liver Dis. 2005;9:329–346
  12. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–1578
  13. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006;355:2444–2451
  14. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677–684
  15. Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009;136:138–148
  16. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875–881
  17. Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology. 2008;135:821–829
  18. Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13:393–397
  19. Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, et al. Lack of benefit of escalating dosage of Interferon alfa in patients with chronic hepatitis C. Gastroenterology. 1995;109:156–165
  20. Chow WC, Boyer N, Pouteau M, Castelnau C, Martinot-Peignoux M, Martins-Amado V, et al. Re-treatment with interferon alfa of patients with chronic hepatitis C. Hepatology. 1998;27:1144–1148
  21. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485–1492
  22. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426–1432
  23. Poynard T, McHutchison JG, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology. 2000;32:1131–1137
  24. Koshy A, Madda JP, Marcellin P, Martinot M. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. J Clin Gastroenterol. 2002;35:82–85
  25. Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, et al. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial. J Viral Hepat. 2003;10:197–204
  26. Manns M, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  27. Poynard T, McHutchison JG, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313
  28. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  29. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  30. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol. 2004;40:993–999
  31. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, Fried MW, Marcellin P, et al. Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial. Am J Gastroenterol. 2004;99:1298–1305
  32. Bonny C, Fontaine H, Poynard T, Hézode C, Larrey D, Marcellin P, et al. Effectiveness of interferon plus ribavirin combination in the treatment of naïve patients with hepatitis C virus type 5. A French multicentre retrospective study. Aliment Pharmacol Ther. 2006;24:593–600
  33. Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology. 2006;131:1040–1048
  34. Bruix J, Sherman M. Management of hepatocellular carcinoma (AASLD Practice Guideline). Hepatology. 2005;42:1208–1236
  35. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430
  36. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554–1568
  37. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289–293
  38. Konishi I, Horiike N, Hiasa Y, Tokumoto Y, Mashiba T, Michitaka K, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2007;37:331–336
  39. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology. 2008;135:111–121

PII: S0168-8278(10)00088-7

doi: 10.1016/j.jhep.2009.12.028

Journal of Hepatology
Volume 52, Issue 5 , Pages 652-657 , May 2010

Article Tools

* Image Usage & Resolution